Research Article
Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer Treatment
Table 2
Characteristics of groups of germ-free mice and donors of stool samples for faecal microbiota transplantation.
| Group of animals | Number of animals | Material for transplantation | Route of administration | Donor of microbiota |
| 1 (control) | 10 | 0.9% NaCl solution | Intragastric | N/A | 2 | 10 | Faecal microbiota sample from donor 1 | Intragastric | Donor 1: female, 48 yo; lung adenocarcinoma T4N1M1a, stIV; PFS, 49 months after the ICI therapy | 3 | 10 | Faecal microbiota sample from donor 2 | Intragastric | Donor 2: male, 71 yo; lung adenocarcinoma T2bN3M1b, stIV; PFS, 5 months after the ICI therapy | 4 | 10 | Faecal microbiota sample from donor 3 | Intragastric | Donor 3: male, 73 yo; lung adenocarcinoma T2bN0M1, stIV; PFS, 7 months after the ICI therapy |
|
|
ICIs: immune checkpoint inhibitors; PFS: progression-free survival; N/A: not applicable; yo: years old.
|